Outset Medical Reports Preliminary Q3 2023 Financial Results; Sees Q3 Revenue $30.4M Vs $27.8M YoY; Total Cash, Including Restricted Cash, Cash Equivalents And Short-Term Investments, Was $197M As Of Sept. 30, 2023
Portfolio Pulse from Benzinga Newsdesk
Outset Medical, Inc. (NASDAQ:OM) reported preliminary Q3 2023 financial results, with revenue of $30.4M, a 9% increase YoY. The company's total cash, including restricted cash, cash equivalents, and short-term investments, was $197M as of Sept. 30, 2023. However, growth in the quarter was affected by the recent FDA warning letter and a cautious outlook on capital spending. The company remains confident about generating sustained long-term growth and reaching profitability.
October 12, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Outset Medical's Q3 2023 revenue increased by 9% YoY to $30.4M. Despite the impact of an FDA warning and cautious capital spending, the company remains confident about its long-term growth and profitability.
Outset Medical's Q3 2023 revenue has increased, indicating a positive financial performance. However, the company has faced challenges due to an FDA warning and a cautious outlook on capital spending, which could potentially impact its short-term performance. Despite these challenges, the company remains confident about its long-term growth and profitability, which could potentially have a positive impact on its stock in the long term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100